lenograstim
Sign in to saveLenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
In the Vinony graph
Vinony's link graph records 229 inbound references to lenograstim, and connects out to interferon gamma, peginterferon alfa-2a and interferon type I.
Vinony files it under Chemical pages without DrugBank identifier, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Vinony links it to 6 Wikipedia language editions.
Research
420 papers- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.The Lancet. Oncology · 2012
- Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.Drugs · 2011
- Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.Drugs · 1995
- G-CSF: filgrastim, lenograstim and biosimilars.Expert opinion on biological therapy · 2014
- Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.Drugs · 2000
via PubMed
Wikidata facts
Show 1 more fact
- defined daily dose
- 0.35
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
== References ==
Excerpted from Wikipedia’s “lenograstim” article, available under the CC BY-SA 4.0 licence.
Available in 6 languages
via Wikidata sitelinks · CC0